COTI-2 inhibited proliferation of multiple cancer cell lines regardless of their genetic makeup and p53 mutational status, and its mechanisms of action include p53 independent pathways potentially including inhibition of mTOR pathways and AMPK activation (Lindemann et al., 2019). The gene discussed is TP53; the disease is cancer.